Active Ingredient(s): Nusinersen
FDA Approved: * December 23, 2016
Pharm Company: * BIOGEN
Category: Neurological Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Spinraza Overview

Nusinersen, marketed as Spinraza,[1] is the first drug approved by the US Food and Drug Administration for use in treating spinal muscular atrophy (SMA), a rare neuromuscular disorder. Contents 1 Medical use 2 Side effects 3 Pharmacology 4 Chemistry 5 History 6 Society and culture 7 References 8 Further reading Medical use The drug is used to treat spinal muscular atrophy associated with a mutation in the SMN1 gene. It is administered directly to the central nervous system (CNS) u...

Read more Spinraza Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Nusinersen

Recent Spinraza Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 2.4mg/ml
  • Solution: 12mg/5ml (2.4mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Spinraza: (1 result)

Sorted by National Drug Code
  • 64406-058 Spinraza 2.4 mg/ml Intrathecal Injection, Solution by Biogen

Other drugs which contain Nusinersen or a similar ingredient: (1 result)